Abstract
We investigated the pharmacokinetics and the effects on sexual maturation and growth of HPBCD complexed SL-T in five prepubertal males aged 14-17 years with CDGP. Patients were treated with 2.5 mg SL testosterone TID for 12 weeks. Patients revealed no evidence of side effects and had greater than 95% compliance with the drug regimen. SL-T raised serum testosterone (T) levels from a baseline of 20±10 to a peak of 1400±120 ng/dl within 20 minutes with a half life of 25±5 minutes. Serum estradiol and gonadotropin levels were not acutely affected by SL-T. SL-T kinetics were not significantly changed after 12 weeks of therapy. In three patients followed over 6-18 months after the SL-T course, sexual maturation stage progressed from stage I to stage II-IV, testicular volume increased from 2±1 to 11±4 ml, growth velocity increased from 4±1 to 11±2 cm/year, and height SDS rode from −2.5±0.2 to −1.8±0.5. Serum testosterone levels increased from 20±10 to 250±100 ng/dl, and serum IGF-I levels rose from 150±30 to 300±60 ng/ml. Bone age advanced from 11±1 to 13±0.5 years over 1.2±0.3 years while predicted adult height remained unchanged. Our preliminary data suggest that a 12 week course of SL-T is a safe, effective, and well accepted treatment for the induction of puberty and the concurrent promotion of growth in male adolescents with CDGP.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cohen, P., Brown, D., Dudley, R. et al. TREATMENT OF ADOLESCENT MALES WITH CONSTITUTIONAL DELAY OF GROWTH AND PUBERTY (CDGP) WITH SUBLINGUAL TESTOSTERONE (SL-T) COMPLEXED WITH HYDROXYPROPYL-β-CYCLODEXTRIN (HPBCD). Pediatr Res 33 (Suppl 5), S85 (1993). https://doi.org/10.1203/00006450-199305001-00493
Issue Date:
DOI: https://doi.org/10.1203/00006450-199305001-00493